The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia

Benjamin Levy, Jon E. Arnason, James B. Bussel

Research output: Contribution to journalReview article

Abstract

Purpose of review This review summarizes the history of the development of thrombopoietic agents and discusses their potential use in chemotherapy-induced thrombocytopenia. Recent findings A new generation of thrombopoietic agents have had preliminary success in the treatment of thrombocytopenia. The initial thrombopoietic agents were recombinant and pegylated human megakaryocyte growth factor. These agents showed promise in the treatment of chemotherapy-induced thrombocytopenia but had the unfortunate side effect of promoting the development of antibodies against endogenous thrombopoietin and subsequent refractory thrombocytopenia. Now, a second generation of synthetic thrombopoietic agents including AMG 531 and eltrombopag have shown promise in the treatment of thrombocytopenia in patients with immune thrombocytopenia purpura and hepatitis C without the development of an immunological response. As these new agents see broader use, many questions regarding their safety and their most effective administration need to be answered. Summary The second generation of thrombopoietic agents has been shown to correct thrombocytopenia in selected diseases with a minimum of side effects. Looking forward, there is great potential for their use in other forms of thrombocytopenia, including chemotherapy-induced thrombocytopenia, but there are also many questions remaining regarding their best and safest use.

Original languageEnglish (US)
Pages (from-to)690-696
Number of pages7
JournalCurrent Opinion in Oncology
Volume20
Issue number6
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Thrombocytopenia
Drug Therapy
Thrombopoietin
Purpura
Idiopathic Thrombocytopenic Purpura
Megakaryocytes
Hepatitis C
Intercellular Signaling Peptides and Proteins
Therapeutics
History
Safety
Antibodies

Keywords

  • Bleeding
  • Hepatitis c
  • Immune thrombocytopenia purpura
  • Platelets
  • Thrombopoietin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. / Levy, Benjamin; Arnason, Jon E.; Bussel, James B.

In: Current Opinion in Oncology, Vol. 20, No. 6, 01.11.2008, p. 690-696.

Research output: Contribution to journalReview article

@article{936f2286c15f40b3a2388f5e9cd5250a,
title = "The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia",
abstract = "Purpose of review This review summarizes the history of the development of thrombopoietic agents and discusses their potential use in chemotherapy-induced thrombocytopenia. Recent findings A new generation of thrombopoietic agents have had preliminary success in the treatment of thrombocytopenia. The initial thrombopoietic agents were recombinant and pegylated human megakaryocyte growth factor. These agents showed promise in the treatment of chemotherapy-induced thrombocytopenia but had the unfortunate side effect of promoting the development of antibodies against endogenous thrombopoietin and subsequent refractory thrombocytopenia. Now, a second generation of synthetic thrombopoietic agents including AMG 531 and eltrombopag have shown promise in the treatment of thrombocytopenia in patients with immune thrombocytopenia purpura and hepatitis C without the development of an immunological response. As these new agents see broader use, many questions regarding their safety and their most effective administration need to be answered. Summary The second generation of thrombopoietic agents has been shown to correct thrombocytopenia in selected diseases with a minimum of side effects. Looking forward, there is great potential for their use in other forms of thrombocytopenia, including chemotherapy-induced thrombocytopenia, but there are also many questions remaining regarding their best and safest use.",
keywords = "Bleeding, Hepatitis c, Immune thrombocytopenia purpura, Platelets, Thrombopoietin",
author = "Benjamin Levy and Arnason, {Jon E.} and Bussel, {James B.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1097/CCO.0b013e32831369b2",
language = "English (US)",
volume = "20",
pages = "690--696",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia

AU - Levy, Benjamin

AU - Arnason, Jon E.

AU - Bussel, James B.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Purpose of review This review summarizes the history of the development of thrombopoietic agents and discusses their potential use in chemotherapy-induced thrombocytopenia. Recent findings A new generation of thrombopoietic agents have had preliminary success in the treatment of thrombocytopenia. The initial thrombopoietic agents were recombinant and pegylated human megakaryocyte growth factor. These agents showed promise in the treatment of chemotherapy-induced thrombocytopenia but had the unfortunate side effect of promoting the development of antibodies against endogenous thrombopoietin and subsequent refractory thrombocytopenia. Now, a second generation of synthetic thrombopoietic agents including AMG 531 and eltrombopag have shown promise in the treatment of thrombocytopenia in patients with immune thrombocytopenia purpura and hepatitis C without the development of an immunological response. As these new agents see broader use, many questions regarding their safety and their most effective administration need to be answered. Summary The second generation of thrombopoietic agents has been shown to correct thrombocytopenia in selected diseases with a minimum of side effects. Looking forward, there is great potential for their use in other forms of thrombocytopenia, including chemotherapy-induced thrombocytopenia, but there are also many questions remaining regarding their best and safest use.

AB - Purpose of review This review summarizes the history of the development of thrombopoietic agents and discusses their potential use in chemotherapy-induced thrombocytopenia. Recent findings A new generation of thrombopoietic agents have had preliminary success in the treatment of thrombocytopenia. The initial thrombopoietic agents were recombinant and pegylated human megakaryocyte growth factor. These agents showed promise in the treatment of chemotherapy-induced thrombocytopenia but had the unfortunate side effect of promoting the development of antibodies against endogenous thrombopoietin and subsequent refractory thrombocytopenia. Now, a second generation of synthetic thrombopoietic agents including AMG 531 and eltrombopag have shown promise in the treatment of thrombocytopenia in patients with immune thrombocytopenia purpura and hepatitis C without the development of an immunological response. As these new agents see broader use, many questions regarding their safety and their most effective administration need to be answered. Summary The second generation of thrombopoietic agents has been shown to correct thrombocytopenia in selected diseases with a minimum of side effects. Looking forward, there is great potential for their use in other forms of thrombocytopenia, including chemotherapy-induced thrombocytopenia, but there are also many questions remaining regarding their best and safest use.

KW - Bleeding

KW - Hepatitis c

KW - Immune thrombocytopenia purpura

KW - Platelets

KW - Thrombopoietin

UR - http://www.scopus.com/inward/record.url?scp=55749105715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749105715&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32831369b2

DO - 10.1097/CCO.0b013e32831369b2

M3 - Review article

C2 - 18841052

AN - SCOPUS:55749105715

VL - 20

SP - 690

EP - 696

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -